Skip to main content

Gaithersburg’s NexImmune acquired by investor consortium of Teva Pharmaceuticals , Celgene Corp. , Medtronic alums – Washington Business Journal

By February 21, 2017News
neximmune-logo

neximmune-logo

Gaithersburg-based NexImmune, a biotech developing immunotherapy treatments for cancer, has been acquired by a consortium of big-name biotech veterans and investors.

{iframe}http://www.bizjournals.com/washington/news/2017/02/14/roivant-sciences.html{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.